Boston Scientifics' (BSX) journey over the past 12 months has displayed its poise as a market leader. On the heels of its $28 billion acquisition of Guidant Corporation earlier this year, Boston Scientific inherited pacemaker and defibrillator recalls. Recent headlines questioned the safety of its drug-eluting stents, linking them to the cause of blood clots in cardiac patients. Last month, Boston Scientific hit a 52-week low of $14.43, the decline driven by fear and negative investor sentiment. While the crowd may flee, investors seeking value must look to the fundamentals that reside beyond the noise of today.

What had happened during the merger? Who won?
When I last wrote about this stock, Boston Scientific had just trumped Johnson & Johnson's (JNJ) offer with a $27.2 billion dollar offer for Guidant. At the time of the acquisition, Guidant was the #2 cardiac rhythm management (CRM) market share leader behind Minneapolis-based Medtronic Inc (MDT). Guidant's CRM products focus on cardiovascular disease, the number one cause of death in the United States. Since Guidant had already accepted the Johnson & Johnson offer, it had to pay a termination fee of $705 million to break the contract before accepting the Boston Scientific offer.


Why did Boston Scientific do it?
Boston Scientific had 9 billion reasons to break into the $9 billion global CRM market. Acquiring Guidant gives Boston Scientific a hedge against sales fluctuations in its primary coronary stent business. The acquisition also gives Boston Scientific more leverage, as it continues to duel with JNJ and future market participants including Medtronic and Abbott Labs for coronary stent market leadership.

Abbott Labs (ABT), the maker of prescription pharmaceuticals, nutritional products and diagnostic equipment, actually purchased Guidant's $1 billion a year revenue-generating vascular intervention and endovascular business prior to the Boston Scientific acquisition. Abbott paid $4.1 billion for Guidant's technology. Abbott agreed however to share the drug-eluting technology it gained from Guidant with Boston Scientific. The additional drug eluting technology compliments Boston Scientifics' current #1 product, its TAXUS Express Paclitaxel-Eluting Coronary Stent system. Abbott Labs made headlines of its own on Monday, November 6th with the announcement of its acquisition of prescription cardiovascular and respiratory drug maker Kos Pharmaceuticals (KOSP).

By The Numbers
On a forward basis, Boston Scientific has a low price to earnings growth (PEG) ratio of 1.01 with a forward price to earnings ratio of 20 and estimated earnings per share growth rate of 20%. Medtronic Inc and Johnson & Johnson weigh in with higher PEG's of 1.42 and 1.81, respectively.

The lower Boston Scientific PEG ratio suggests that its expected annual growth rate exceeds the expectations for both Medtronic Inc and Johnson & Johnson. Boston Scientific reported an increase in net sales of 34% for the third quarter ending September 30th over the year ago period, the increase primarily driven by sales from its CRM business. Since the Guidant acquisition, CRM and Cardiac Surgery have contributed $965 million,or 17% of its worldwide revenues, to BSX through September 30th.

Hype Over Bite

The recent headlines concerning the possibility of blood clots forming in conjunction with the use of the Taxus stent appears to have more hype than bite. In late October, the Cardiovascular Research Foundation confirmed that the Taxus stent is safe and effective. Along with a virtual monopoly on drug-coated stents between itself and Johnson & Johnson for the immediate future, Boston Scientific also has demographics on its side.

With a well-documented aging U.S. population and a fast-graying Japanese population on the horizon, demand for Boston Scientifics' minimally invasive life saving and life extending products are more than likely to benefit future patients and fall in-line with management's bright expectations. With a diverse and innovative product line in place to combat competition and an uncanny ability to move beyond negative news, Boston Scientific is very likely trading at a discount in comparison to where it will be in the years to come.

Related Articles
  1. Stock Analysis

    5 Cheap Dividend Stocks for a Bear Market

    Here are five stocks that pay safe dividends and should be at least somewhat resilient to a bear market.
  2. Stock Analysis

    The Biggest Risks of Investing in Amazon Stock

    Find out which risks are most important to Amazon's shareholders. Learn which operational risks impact share prices and which financial risks affect investors.
  3. Investing

    How to Win More by Losing Less in Today’s Markets

    The further you fall, the harder it is to climb back up. It’s a universal truth that is painfully apparent in the investing world.
  4. Fundamental Analysis

    Use Options Data To Predict Stock Market Direction

    Options market trading data can provide important insights about the direction of stocks and the overall market. Here’s how to track it.
  5. Stock Analysis

    2 Oil Stocks to Buy Right Now (PSX,TSO)

    Can these two oil stocks buck the trend?
  6. Investing News

    What Alcoa’s (AA) Breakup Means for Investors

    Alcoa plans to split into two companies. Is this a bullish catalyst for investors?
  7. Stock Analysis

    Top 3 Stocks for the Coming Holiday Season

    If you want to buck the bear market trend by going long on consumer stocks, these three might be your best bets.
  8. Investing News

    Could a Rate Hike Send Stocks Higher?

    A rate hike would certainly alter the investment scene, but would it be for the better or worse?
  9. Fundamental Analysis

    What's eBay Without PayPal?

    In July 2015, eBay completed its spinoff of PayPal and sold its Enterprise segment. We take a look at eBay's remaining lines of business.
  10. Investing Basics

    These Industries Have The Most Illiquid Stocks

    U.S. equity markets are vast and highly liquid, but a few sectors have failed to attract substantial capital.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!